Objectives: Depression and medication nonadherence are important in managing chronic diseases, but little is known about these factors in childhood-onset systemic lupus erythematosus (cSLE). The objectives of this cross-sectional study were to estimate prevalence of depression and medication nonadherence, describe demographic and disease characteristics associated with depression and medication nonadherence, and evaluate the association between depression and medication nonadherence in cSLE patients. Methods: Patients with cSLE (n ¼ 51) completed validated screening questionnaires to identify depression and medication nonadherence, Patient Health Questionnaire-9 and Medication Adherence Self-Report Inventory, respectively. Demographic and disease characteristics were obtained via chart abstraction, and compared between groups of depression or medication nonadherence status. A multivariable linear regression model adjusting for propensity scores was conducted to evaluate the association between depression and medication nonadherence. Results: The prevalence of a positive depression screen was 58.8%, and seven patients reported suicidal ideation (13.7%). The prevalence of self-reported medication nonadherence was 19.7%. No statistically significant differences for demographic and disease characteristics were found between patients with a positive vs. negative depression screen. Patients reporting medication nonadherence were more likely to have longer disease duration (4.8 vs. 2.6 years, p ¼ 0.035). As the severity of depression symptoms increased, the degree of medication nonadherence also increased (beta ¼ -1.89; p ¼ 0.011). Conclusions: The prevalence of depression and medication nonadherence is high in cSLE, and these factors have a direct relationship. Interventions that better recognize and treat depression and increase rates of medication adherence are needed to improve outcomes in cSLE. Lupus (2018) 27, 1532-1541.
Introduction
Childhood-onset systemic lupus erythematosus (cSLE) is characterized by rapid accrual of organ damage with one-third of patients suffering cerebrovascular accidents, renal failure, and/or scarring alopecia within five years of disease onset, [1] [2] [3] [4] making interventions to improve health outcomes for this vulnerable population of children an urgent need. Depression and medication nonadherence are two intervention targets that have the potential to improve outcomes in cSLE, but little is known about depression, medication nonadherence, and the relationship of these two factors in cSLE.
Depression is cited as the most significant predictor of poor health-related quality of life in adults with SLE. 5 Furthermore, depression is a known risk factor for nonadherence to chronic medical treatment; 6, 7 and poor adherence has been associated with increased disease activity, increased ambulatory care and emergency room visits, and overall poor prognosis in adults with SLE. [8] [9] [10] [11] Despite this knowledge, few studies have evaluated rates of depression and factors associated with depression in cSLE. [12] [13] [14] Likewise, only one study has measured the rate of medication nonadherence in cSLE, and factors associated with medication nonadherence in this population were not assessed. 15 No known studies have evaluated the association of depression and medication nonadherence in cSLE.
The objectives of this cross-sectional study were to estimate the prevalence of depression and medication nonadherence, describe demographic and disease characteristics associated with depression and medication nonadherence, and evaluate the correlation between depression and medication nonadherence in patients with cSLE.
Methods

Participants and procedures
For this cross-sectional study participants were recruited between January 11, 2016 and October 20, 2016 from the Pediatric Rheumatology Clinic at Monroe Carell Jr. Children's Hospital at Vanderbilt, a moderate-sized practice within an urban academic institution. The clinic serves a diverse population in terms of age, ethnicity, and insurance status throughout Tennessee and the surrounding states.
Potential participants were identified using a registry created via query of the electronic medical record for all clinic patients billed under the International Classification of Diseases, Ninth Revision (ICD-9) code 710.0 during the prior two years. Patients who had been newly diagnosed with cSLE or who had a known diagnosis of cSLE and were establishing care in the clinic during the study period were manually added to the registry. Eligibility criteria included a diagnosis of cSLE confirmed using the American College and Rheumatology (ACR) or the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, presence of prescribed medication for management of SLE for at least one month, and ability to complete the consent process and necessary study questionnaires in English.
Patients were invited to participate in the study upon arrival for a scheduled clinic visit by one of two designated clinic nurses who were not directly related to the check-in process or solely responsible for the patient's medical care during that clinic visit. Completion of study procedures while in clinic ensured that health care providers and study personnel were appropriately positioned to intervene should suicidal and/or homicidal ideation be identified on the depression screen. During the consent process participants were asked to acknowledge the required breach of confidentially should his or her safety or the safety of those around him or her be compromised. Each study participant was also asked to choose whether he or she would like to discuss his or her results of the depression screen with a medical provider during the clinic visit. A clinic nurse reviewed the depression screen prior to each participant's discharge from clinic in order to identify and address such information in a time-sensitive manner. Protocol dictated that participants with active suicidal ideation were transferred to the emergency room for urgent evaluation by a mental health team, while those with passive suicidal ideation completed a safety plan with the primary health care provider and/or social worker in clinic and were referred to outpatient mental health services.
Data were collected and stored within Research Electronic Data Capture (REDCap), a secure, Health Insurance Portability and Accountability Act-compliant web-based application recommended to Vanderbilt researchers by both the privacy office and the institutional review board (http:// www.projectredcap.org). Questionnaires used in this study were transcribed in REDCap and administered electronically using an iPad. Demographic and disease activity information for participants was obtained via chart abstraction and transferred directly from the electronic medical record (EMR) to REDCap. Direct entry of data into the electronic database minimized transcription errors and missing data points that could potentially bias the study.
All study procedures were reviewed and approved by the Vanderbilt University Institutional Review Board (#151619). All patients and caregivers, as appropriate based on patient age, provided written informed consent to participate. Access to research materials related to the study may be gained by contacting the corresponding author.
Measures
The Patient Health Questionnaire-9 (PHQ-9) was used to measure the presence or absence of depression symptoms. The PHQ-9 is a nine-item depression screen based on the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for major depression 16 that has been validated for use in an adolescent population. 17 Each symptom criterion is assessed by a question regarding feelings during the last two weeks and is scored on a scale from 0 (not at all) to 3 (nearly every day) generating a total score range of 0-27. The categorical scoring algorithm defines mild depression as scores of 5-9, moderate depression as scores of 10-14, moderately severe depression as scores of 15-19, and severe depression as scores of 20-27 with any affirmative response to question 9 regarding suicidal ideation yielding a positive screen regardless of the total score.
Medication nonadherence was measured using the Medication Adherence Self-Report Inventory (MASRI). The MASRI is a 12-item questionnaire of self-reported medication adherence measuring both frequency and timing of medication administration. It includes a visual analog scale (VAS) from 0% to 100% used to estimate adherence rate during the preceding one month. Higher percentages on the VAS indicate a greater degree of medication adherence. 18 The MASRI has been found to be both reliable and valid in a cohort of patients with SLE that included adolescents. 19 Although all questions regarding the frequency of medication administration were asked in accordance with the validation study methods, only results from the VAS score were used in the primary analysis of this study.
Covariates
Participant demographics, disease characteristics, and medication information were collected directly by the principal investigator from the EMR using a standardized chart abstraction form. Participant demographics included age, sex, race, and insurance type. Disease characteristics included age at diagnosis, disease duration, presence of lupus nephritis, and presence of a known mental health disorder. Presence of lupus nephritis was determined based on documentation of this diagnosis within a rheumatology note or nephrology note in the EMR; renal biopsy results were reviewed when available to confirm this diagnosis. Presence of a known mental health disorder was defined as having had a prior psychiatry appointment at the study site institution or documentation within a rheumatology note of mental health care received at an outside institution during the year preceding study enrollment or the presence of a current prescription for a psychotropic medication. Medication information included a count of all prescribed and scheduled medications (including infusions), names of medications, and weight-based oral glucocorticoid steroid dose.
Disease activity scores were also collected at time of enrollment using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). The SLEDAI is a validated tool widely used in SLE research that has been shown to be a sensitive measure of disease activity both in adults and children with SLE. 20, 21 Each SLEDAI form was completed by the participant's primary rheumatology provider and transcribed into the REDCap database by the principal investigator.
Statistical analysis
The prevalence of depression and medication nonadherence in the study population was calculated.
Comparisons of demographic and disease characteristics between groups with and without depression and between groups with and without medication nonadherence were conducted using the Wilcoxon rank sum test for continuous variables and chi squared test or Fisher's exact test for categorical variables, as appropriate. The propensity score (PS) method was applied to estimate the probability of positive depression screen (PHQ-9 score ! 5) using a proportional odds regression model including all the above listed covariates: age, sex, race, insurance type, age at diagnosis, disease duration, disease activity score, number of medications, weight-based oral glucocorticoid steroid dose, presence of lupus nephritis, and presence of a known mental health disorder. A multivariable linear regression was performed to model MASRI score against PHQ-9 score adjusting for one covariate, the linear predictors of having a positive depression screen from the PS model. Restricted cubic splines with three knots were applied on the linear predictors to account for skewed data. The PS method is an accepted data reduction technique that enables adjustment for multiple covariates within the regression analysis despite a small sample size without risking model overfitting. [22] [23] [24] A subgroup analysis limited to participants with ages between 12 and 18 years was conducted using the above described PS method. A sensitivity analysis excluding the two data points defined as statistical outliers was also conducted using the above described PS method. Post-hoc analysis of participants with suicidal ideation was completed; comparisons of demographic and disease characteristics between groups with and without suicidal ideation were conducted using the Wilcoxon rank sum test or Fisher's exact test, as appropriate.
All data analyses were conducted using STATA 14.1 statistical software (StataCorp, College Station, TX).
Results
A total of 51 participants were enrolled in the study. The registry included 67 potentially eligible Depression and medication nonadherence in cSLE AM Davis et al.
patients, but 11 patients did not present for a clinic appointment at the study site during the study period. An additional three patients did not meet ACR and/or SLICC classification criteria for cSLE and were excluded from the study. One patient was excluded from the study because the consenting caregiver was unable to read English. Only one invited patient declined to participate (Figure 1 ). Data from all enrolled participants were included in the analysis. There were no missing data points. Two participants under the age of 10 years completed the study questionnaires with assistance from the accompanying parent.
The mean age of the study participants was 16.2 (3.3) years with an age range from 7 to 22 years. Most of the participants were female (47, 92.2%). More than half of the study population was black (27, 52.9%). The remainder of reported races were white (15, 29.4%), Asian (5, 9.8%), Hispanic (3, 5.9%), and other (1, 2.0%). Medicaid provided primary insurance for the greatest number of participants (29, 56.9%), followed by commercial insurance (21, 41.2%) and military insurance (1, 2.0%). The mean disease duration for the study participants was 3.0 (2.9) years. Average SLEDAI score was 5.1 (5.5); the median SLEDAI score was 4 with an interquartile range (IQR) of 1.0-7.0. Lupus nephritis was present in more than onethird of the study population (20, 39.2%). The mean number of prescribed and scheduled medications was 6.7 (2.8) with a range between 1 and 14. The majority of the participants were prescribed oral glucocorticoid steroids (44, 86.3%) with a mean prednisone dose of 0.15 (0.10) mg/kg/day. Nearly all participants were prescribed hydroxychloroquine (50, 98.0%). Mycophenolate mofetil was the next most commonly prescribed immunomodulatory medication (35, 68.6%). Other Figure 1 Of the 67 potentially eligible patients identified, a total of 51 patients were enrolled in the study. Only one patient declined to participate, and only one patient was excluded because of the patient caregiver's inability to complete the consent process in English. ACR: American College of Rheumatology; EMR: electronic medical record; ICD-9: International Classification of Diseases, Ninth Revision; SLICC: Systemic Lupus International Collaborating Clinics. prescribed immunomodulatory medications included azathioprine (4, 7.8%), methotrexate (3, 5.9%), and tacrolimus (2, 3.9%). Few participants were receiving scheduled immunomodulatory infusions of belimumab (4, 7.8%) and cyclophosphamide (1, 2.0%). Approximately one-third of the population had documentation of receiving mental health services (16, 31.4%).
The prevalence of a positive depression screen, defined as a PHQ-9 score ! 5 or any affirmative response to question 9 regarding the presence of suicidal ideation, was 59%. Seven patients reported suicidal ideation. This number represents 14% of the study population and 23% of those individuals with a positive depression screen. The prevalence of medication nonadherence, defined as a MASRI score 80% on the VAS, was 20%. The mean MASRI score for the entire study population was 88%.
Demographic and disease characteristics for patients with and without a positive depression screen are summarized in Table 1 . No statistically significant differences between these groups were found. Demographic and disease characteristics for patients reporting medication adherence and medication nonadherence are summarized in Table 2 . Participants who reported medication nonadherence were more likely to have longer disease duration than patients who reported medication adherence (4.8 vs. 2.6 years, p ¼ 0.035). No statistically significant differences were found between these groups for the remainder of variables.
A multivariable linear regression adjusting for the linear predictors from the PS model incorporating the aforementioned covariates demonstrated that depression was significantly associated with nonadherence (beta coefficient ¼ -1.89; p ¼ 0.011). The regression model result indicates that as the severity of depressive symptoms increases, the degree of medication nonadherence also increases. Specifically, for every one-point increase in the PHQ-9 score, the MASRI score decreases by approximately two points when controlling for Depression and medication nonadherence in cSLE AM Davis et al.
the linear predictors. Figure 2 shows the linear prediction of MASRI score by PHQ-9 score. The subgroup analysis limited to participants with ages between 12 and 18 years included 36 participants, 70% of the total cohort. Results were consistent with findings from the complete cohort and remained statistically significant (beta coefficient ¼ À2.42; p ¼ 0.013). Specifically, the direction of the relationship between depression and medication nonadherence was maintained, but the magnitude of the relationship was greater in the subgroup analysis compared to that of the complete cohort. The sensitivity analysis excluding the two statistical outliers with the lowest MASRI scores also produced similar results. The direction of the relationship was again maintained, but the magnitude of the relationship was diminished and did not retain statistical significance (beta ¼ -0.34; p ¼ 0.481).
Demographic and disease characteristics for patients with and without suicidal ideation are summarized in Table 3 . All patients reporting suicidal ideation had PHQ-9 scores ! 5 (i.e. no patients had a positive depression screen solely based on an affirmative response to question 9 regarding the presence of suicidal ideation). Participants who reported suicidal ideation were diagnosed with cSLE at a younger age compared to participants who did not report suicidal ideation (9.0 vs 13.8 years, p ¼ 0.001). No statistically significant differences were found between these groups for the remainder of variables.
Discussion
The prevalence of a positive depression screen in this study population of patients with cSLE was high (59%). This finding is only slightly higher than the prevalence of depression in cSLE reported in prior studies (20%-57%). [12] [13] [14] Prevalence in this study may be higher because of the use of a positive depression screen as a surrogate marker for depression. Screening tools are designed to be particularly sensitive and as a result may identify some false positives. Perhaps even more striking than the high rate of depression in cSLE is the high rate of reported suicidal ideation. Nearly one-quarter (23%) of participants in this study who had a positive depression screen reported suicidal ideation at the time of the screen. This number represents 14% of the total study population. Again, this estimate is similar to that reported in previous studies in which the prevalence of suicidal ideation in pediatric patients with SLE ranges between 14% and 34%. 14, 25, 26 This prevalence is disproportionately higher than those observed in healthy Figure 2 The regression analysis shows that as the severity of depressive symptoms increases, the degree of medication nonadherence also increases when controlling for the linear predictors from the propensity score analysis. CI: confidence interval; MASRI: Medication Adherence Self-Report Inventory; PHQ-9: Patient Health Questionnaire-9.
Depression and medication nonadherence in cSLE AM Davis et al. controls 14, 27, 28 and those reported for children with special health care needs and other chronic diseases such as Type I diabetes mellitus and asthma. [29] [30] [31] Although none of the participants in this study posed an immediate suicide risk, the results support a need for increased awareness and capacity to identify and intervene in patients with cSLE who appear to be at particular risk for depression and suicidal ideation.
Predictors of a positive depression screen were not identified, as there were no significant differences between patients with and without a positive depression screen. This lack of predictive patient characteristics with the above noted high prevalence supports the need for universal depression screening in this population. A study conducted by The Childhood Arthritis and Rheumatology Research Alliance showed that 77% of pediatric rheumatologists agreed routine depression screening in pediatric rheumatology patients should be conducted, but only 2% of the surveyed pediatric rheumatologists reported completing routine screening using standardized tools and protocols, with limited staff resources and time being cited as the most frequent barrier to routine screening. 32 Participants who had presence of suicidal ideation were more likely to have been diagnosed with cSLE at a younger age. Thus, patients diagnosed with cSLE at a young age may represent a subpopulation that warrants more frequent screening for depression and suicidal ideation or other forms of intervention. Interestingly, participants receiving mental health services were not necessarily more likely to have higher or lower depression screen scores nor presence or absence of suicidal ideation. This may relate to current efficacy of mental health interventions, but remains an area largely unexplored in patients with cSLE.
The prevalence of medication nonadherence in this study population of patients with cSLE was also notable with 20% of the participants reporting less than 80% adherence with SLE medications during the preceding month. This percentage is likely to be an underestimation of the true rate of medication nonadherence given that it was measured using a tool that relies on patient selfreport. In addition, patients who did not present for a clinic visit during the study period were potentially nonadherent to the suggested frequency of clinic visits. This subset of patients may be at increased risk for medication nonadherence, but would not have been captured in the analysis. A previously published study used drug blood levels, pharmacy refill data, and the MASRI to measure adherence to hydroxychloroquine in cSLE. This study found that medication adherence estimates using hydroxychloroquine blood levels correlated with rates measured using pharmacy refill data and the MASRI. However, the mean adherence rates measured with the MASRI were the highest at 80%, which is a similar estimate to our study and supports the idea that MASRI results tend to overestimate adeherence. 15 Additionally, a recently published review of medication adherence in adults with SLE reported a prevalence of nonadherence measured by varying methods ranging from 43% to 75%. 33 Patients who reported medication nonadherence in this study were more likely to have longer disease duration than those who reported medication adherence. Given the relatively large number of statistical tests completed on this small sample size, the risk that this statistical significance was due to chance must be considered. Nonetheless, this finding is consistent with studies looking at medication nonadherence in adults with SLE 33 and aligns with clinical experience in which patients with cSLE become less attentive to disease management as their initial presenting symptoms are not as vividly recollected. Additional predictors of medication nonadherence were not identified, even with inspection of the two outliers with the lowest MASRI scores. As with depression, this lack of predictive patient characteristics and the above noted high prevalence support the need for universal medication adherence assessment in patients with cSLE.
The association between depression and medication nonadherence has been unexplored in cSLE. To our knowledge, this is the first study to assess for an association between depression and medication nonadherence in this specific population. Results from the multivariable linear regression in this study showed a small but significant relationship between depression and medication nonadherence. The model showed that as the severity of depression symptoms increased the degree of medication nonadherence also increased. Specifically, for every one point increase in the PHQ-9 score, the MASRI score decreased by nearly two points. Similar relationships between depression and medication nonadherence have been reported in other chronic diseases, 6 including childhood-onset diseases such as Type I diabetes mellitus and inflammatory bowel disease. 34, 35 In addition, depressive symptoms have been found to be a predictor of medication nonadherence in adults with SLE. 7, 36, 37 The relationship between depression and medication nonadherence was slightly more pronounced for participants with ages between 12 and 18 years. Specifically, the subgroup analysis demonstrated that for every one-point increase in PHQ-9 score, the MASRI score decreased by two and a half points. In addition, the direction of the relationship between depression and medication adherence was maintained even when excluding the two participants with the lowest MASRI scores, though the magnitude of the relationship was smaller and did not retain statistical significance given the reduced sample size. While these two data points are statistically defined as outliers, we believe they actually reflect the spectrum of results expected for this population. Additional chart review was completed to check the validity of the data to ensure the outliers were neither inaccurate nor implausible. No data entry errors were found and both participants were confirmed to have had poor medication adherence-one had documented discussions regarding poor medication adherence within clinic notes preceding the study date and the other subsequently had undetectable mycophenolate mofetil blood levels. Furthermore, no discrete demographic or disease characteristic differences were identified in these two participants compared to the remainder of the cohort, thereby supporting the conclusion that there is a need for universal medication adherence assessment, possibly by multiple methods, in patients with cSLE. Alternatively, larger studies to better determine who is most at risk for medication nonadherence are needed.
The primary limitation of this study is an inability to discern the directionality of the relationship observed. The cross-sectional study design can be used only to identify associations, not to determine causality. Given that depression is a known symptom of neuropsychiatric SLE, the alternative temporal relationship must be considered. The small sample size and single-site design is also a limitation, as it may affect the accuracy of the regression model and generalizability of the study results. However, the sample size was sufficient to detect a statistically significant difference between groups, as was predicted by a priori power calculations. In addition, the sample size in this study is similar to that reported in prior studies addressing rates of depression and medication nonadherence in cSLE. 12, 14 Furthermore, nearly 80% of the convenience sample was recruited with only one patient declining to participate, thereby limiting selection bias. Another limitation is that only covariates available within the EMR could be measured in this preliminary study. Specifically, potentially relevant psychosocial factors could not be assessed (i.e. household income, household education level, caregiver marital status, presence of siblings). However, measuring the types of insurance could be considered as a proxy for socioeconomic status, and no statistically significant difference between insurance groups was found.
The tools used to define the exposure and outcome (PHQ-9 and MASRI, respectively) of the study each have inherent limitations. The PHQ-9 is a screening tool, and while the tool was designed based on diagnostic criteria for major depression, it is not a diagnostic tool. Rather, the results from the PHQ-9 are used as a proxy measure for a diagnosis of depression. As a result, there is a potential for exposure misclassification. The MASRI relies on self-report of medication nonadherence. While efforts are made to promote accurate reporting, there remains a risk for recall bias and social desirability bias. Nonetheless, the tools used in this study are standardized and validated in the population of interest, thereby limiting the overall risk of misclassification and information bias. In addition, the ability to use them within the clinical setting allowed for capture of information regarding suicidal ideation that might not have been ethical to obtain using other study designs.
This study adds to the literature reporting high rates of depression and suicidal ideation in patients with cSLE, is one of the only studies reporting rates of medication nonadherence in this population, and is the first known study that provides preliminary evidence that depression and medication nonadherence are related in cSLE. Furthermore, this study has demonstrated feasibility of administering depression and medication nonadherence screens within a clinical setting. Feasibility is important because developing and evaluating interventions to improve depression and medication nonadherence first requires measurement of these factors at the point of service. Prospective multicenter cohort studies are needed to better understand the relationship of depression and medication nonadherence and to identify potential risk factors for depression and medication nonadherence. Such research will help inform the development of improved systems of care to ameliorate depression and medication nonadherence, thereby improving health outcomes for this vulnerable population of children.
